Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Busulfan intravenous - Otsuka Pharmaceutical

Drug Profile

Busulfan intravenous - Otsuka Pharmaceutical

Alternative Names: Busilvex; Busulfan injection - Orphan Medical; Busulfex; IV busulfan - Otsuka; KRN 246

Latest Information Update: 13 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orphan Medical; PDL BioPharma
  • Developer Grupo Biotoscana; Kirin Holdings Company; Orphan Medical; Otsuka Pharmaceutical; Tzamal Pharma
  • Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Haematological malignancies
  • Phase II Multiple myeloma; T-cell lymphoma

Most Recent Events

  • 09 May 2019 Otsuka Pharmaceutical completes a phase II trial in Multiple myeloma in South Korea, before May 2019 (IV)
  • 10 Mar 2019 Otsuka completes a phase III trial in Multiple myeloma (Combination therapy) in USA (IV) (NCT01413178)
  • 04 Oct 2018 Registered for Haematological malignancies in Chile (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top